45 CFR § 180 compliance
C · 70
This hospital published part of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
○Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
28,134
Insurances with rates
12
CPT / HCPCS codes
15,008
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 428661507 | AXICABTAGENE CILOLEUCEL INTRAVENOUS SUSPENSION (RESTRICTED) [177896] | $2,683,296 | $1,341,648 | — | — | 0 |
| 428663982 | INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION [186780] | $968,502 | $484,251 | — | — | 0 |
| 428665359 | NUSINERSEN (PF) 12 MG/5 ML INTRATHECAL SOLUTION [174701] | $824,956 | $412,478 | — | — | 0 |
| 428666800 | TREMELIMUMAB-ACTL 20 MG/ML INTRAVENOUS SOLUTION [195049] | $362,317 | $181,158 | — | — | 0 |
| 428663983 | INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION [186780] | $322,834 | $161,417 | — | — | 0 |
| 428664667 | LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION [178865] | $322,834 | $161,417 | — | — | 0 |
| 428663615 | GLUCARPIDASE 1,000 UNIT INTRAVENOUS SOLUTION [116024] | $319,181 | $159,591 | — | — | 0 |
| 428666803 | TREMELIMUMAB-ACTL 20 MG/ML INTRAVENOUS SOLUTION [195049] | $308,375 | $154,188 | — | — | 0 |
| 428667135 | YTTRIUM 90 IBRITUMOMAB (ZEVALIN) INTRAVENOUS INJECTION [41815] | $299,271 | $149,636 | — | — | 0 |
| 428664668 | LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN 27 MCI/ML (1,000 MBQ/ML) IV SOLN [192514] | $294,044 | $147,022 | — | — | 0 |
| 27400123 | HC MOBILE POWER UNIT # 119923 | $276,898 | $138,449 | — | — | 0 |
| 428662923 | ECULIZUMAB 300 MG/30 ML INTRAVENOUS SOLUTION [81696] | $237,646 | $118,823 | — | — | 0 |
| 428665609 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION [107664] | $227,280 | $113,640 | — | — | 0 |
| 428665610 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION [107664] | $227,280 | $113,640 | — | — | 0 |
| 428666867 | USTEKINUMAB 90 MG/ML SUBCUTANEOUS SYRINGE [108054] | $215,838 | $107,919 | — | — | 0 |
| 27800223 | HC CANNULA PROTEKDUO #117832 | $212,010 | $106,005 | — | — | 0 |
| 428666807 | TREPROSTINIL 32 MCG CARTRIDGE WITH INHALER [193354] | $209,531 | $104,765 | — | — | 0 |
| 428661082 | ALGLUCOSIDASE ALFA 50 MG INTRAVENOUS SOLUTION [76353] | $199,071 | $99,535 | — | — | 0 |
| 27800095 | HC Y-90 SIR SPHERES ISOTOPE | $193,135 | $96,568 | — | — | 0 |
| 428665828 | PORFIMER 75 MG INTRAVENOUS SOLUTION (RESTRICTED) [14472] | $180,800 | $90,400 | — | — | 0 |
| 428662930 | ECULIZUMAB 300 MG/30 ML INTRAVENOUS SOLUTION [81696] | $178,235 | $89,117 | — | — | 0 |
| 428663990 | INOTUZUMAB OZOGAMICIN 0.9 MG(0.25 MG/ML INITIAL CONCENTRATION) IV SOLN [177438] | $174,956 | $87,478 | — | — | 0 |
| 27800106 | HC DEVICE ASSIST CARDIOHELP HLS # 105701 | $166,777 | $83,389 | — | — | 0 |
| 428666157 | RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS PEN INJECTOR [190211] | $162,927 | $81,464 | — | — | 0 |
| 428666158 | RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE [190212] | $162,927 | $81,464 | — | — | 0 |
| 428666159 | RISANKIZUMAB-RZAA 180 MG/1.2 ML (150 MG/ML) SUBCUT WEARABLE INJECTOR [195523] | $162,927 | $81,464 | — | — | 0 |
| 428666160 | RISANKIZUMAB-RZAA 180 MG/1.2 ML (150 MG/ML) SUBCUT WEARABLE INJECTOR [195523] | $162,927 | $81,464 | — | — | 0 |
| 428666161 | RISANKIZUMAB-RZAA 360 MG/2.4 ML (150 MG/ML) SUBCUT WEARABLE INJECTOR [193426] | $162,927 | $81,464 | — | — | 0 |
| 428666162 | RISANKIZUMAB-RZAA 360 MG/2.4 ML (150 MG/ML) SUBCUT WEARABLE INJECTOR [193426] | $162,927 | $81,464 | — | — | 0 |
| 428666617 | TEBENTAFUSP-TEBN 100 MCG/0.5 ML INTRAVENOUS SOLUTION [192045] | $157,056 | $78,528 | — | — | 0 |
| 428665372 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION (RESTRICTED) [175495] | $152,826 | $76,413 | — | — | 0 |
| 27800287 | HC ANGIOVAC FULL UNIT KIT GEN II # 106792 | $148,980 | $74,490 | — | — | 0 |
| 27800403 | HC PROTEK LIFESPRARC #130259 | $148,980 | $74,490 | — | — | 0 |
| 27800107 | HC DEVICE ASSIST CENTRIMAG BLOOD#50590 | $144,396 | $72,198 | — | — | 0 |
| 428665816 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION (RESTRICTED) [183198] | $140,074 | $70,037 | — | — | 0 |
| 33300061 | HC RADIATION DELIVERY STEREOTACTIC CRANIAL COBALT | $139,610 | $69,805 | — | — | 0 |
| 36101232 | HC INSRT/RPLCMT SPINE GENERATOR OR RECEIVER | $130,396 | $65,198 | — | — | 0 |
| 428663954 | IMMUNE GLOB G 40 GRAM/400 ML(10%)-GLY-IGA AVE 46 MCG/ML INJECTION SOLN [164906] | $128,528 | $64,264 | — | — | 0 |
| 428663966 | IMMUNE GLOB G 40 GRAM/400 ML(10%)-GLY-IGA AVE 46 MCG/ML INJECTION SOLN [164906] | $128,528 | $64,264 | — | — | 0 |
| 428661037 | AGALSIDASE BETA 35 MG INTRAVENOUS SOLUTION [35775] | $124,738 | $62,369 | — | — | 0 |
| 428661039 | AGALSIDASE BETA 35 MG INTRAVENOUS SOLUTION [35775] | $124,738 | $62,369 | — | — | 0 |
| 428661041 | AGALSIDASE BETA 35 MG INTRAVENOUS SOLUTION [35775] | $124,738 | $62,369 | — | — | 0 |
| 428662934 | EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11,200 UNIT/5.6 ML SUBCUT SOLN [192930] | $122,273 | $61,136 | — | — | 0 |
| 428662928 | ECULIZUMAB 300 MG/30 ML INTRAVENOUS SOLUTION [81696] | $118,823 | $59,412 | — | — | 0 |
| 428663957 | IMMUNE GLOBULIN 10% (GAMMAGARD) INTRAVENOUS SOLUTION [167870] | $115,279 | $57,639 | — | — | 0 |
| 428665332 | NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION [192503] | $114,909 | $57,455 | — | — | 0 |
| 48100130 | HC INSJ PERM CCM-D SYS PG&ELTRD | $110,613 | $55,307 | — | — | 0 |
| 428661803 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION [105644] | $109,664 | $54,832 | — | — | 0 |
| 428661804 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION [105644] | $109,664 | $54,832 | — | — | 0 |
| 428661354 | ANDEXANET ALFA 200 MG INTRAVENOUS SOLUTION (RESTRICTED) [182120] | $109,296 | $54,648 | — | — | 0 |
Showing top 50 of 28,134 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.